SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA
Sonoma Pharma (Nasdaq: SNOA)
Market Cap: 22.1 Million Cash: $12.6 Million Price: $5.15
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment •Mondoxyne for severe acne –launched late 2015 •Ceramax for skin repair in atopic dermatitis–launched in April 2016 •SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017 •Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
Vitro Biopharma Reports Positive Clinical Trial Results of Stem Cell Activation Therapy for Autism
GOLDEN, CO / ACCESSWIRE / August 8, 2017 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma, announced initial results of a Phase I clinical trial testing the effects of its proprietary stem ...
I'm absolutely mlnd-blown by the lncredible pr0flt opp0rtunities provlded by PennySt0ck lOl.org... you need to check them out now!
AMGN may be a compelling opportunity. if you guys have questions you should ask awe*some*sto-cks. They often respond to my emails which is helpful.
The Top Newsletter for NASDAQ & NYSE cheapies that make HUGE GAINS --> go to Penny St0cklOl.0rg
I'm absolutely mlnd-blown by the lncredible pr0flt opp0rtunities provlded by T0pMarket Galners.com - you need to check them out now!
The report looked good to me. I don't see any reason for it being down in after hours.
Down after earnings, but I see a potential break-out and new highs
whooz yor daddy
Buy the dip: ....operating margin improved by 4.9 percentage points to 48.4%. AMGN also raises its FY17 adjusted EPS outlook to $12.15-$ 12.65 from $12-$12.60 and narrowed its revenue guidance to a range of $22.5B to $23B. The company reports adjusted EPS of $3.27 on $5.81B in sales,
lets see the low end of guidance they lowered when they have consistently beaten the high end --by 5% plus for quite a while....stupid people selling is what i see.... just hold on will recoup this 2-3% within a week or two and be well above 180...i see 200 by year end ...but thats just my humble opinion
Good signs...AMGN inching back up after the over-reaction from the post earnings sell off.
Like Shep cant find why it is down? either some big players have sold or they have bad guidance?
AMGN has just seen the last of the selling. Looks like a potential push higher is in store. google Awe.Som.e.Stocks. - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
whooz yor daddy
Anyone like AZN on the dip? They seem to have many oncology drugs that are profitable
Today was not good for people who are just chasing earnings short term. However, I've been long Amgen for a while and my $160 buy back in April still is looking good. I fully anticipate that we will be seeing $200 per share in the near future and I've looked at the pipeline on the website and they are in phase 3 on a number of drugs. Can you imagine the share price if Amgen is the first to develop a working Alzheimer's drug.
Who do you think will be 1st for Alzheimer's Amgen, Astra Zeneca, or Biogen?